⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2024

Figure S2 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Prostate cancer cell sensitivity to PLK1 inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nouri et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efedc4 https://doi.org/10.1158/1535-7163.27142524

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer2024
2Figure S5 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer2024
3Figure S6 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer2024
4Table S6 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer2024
5Table S5 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer2024